Vera Therapeutics (VERA) Non-Current Assets (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Non-Current Assets data on file, last reported at $5.9 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 45.12% year-over-year to $5.9 million; the trailing twelve-month figure through Mar 2026 stood at $25.2 million (up 62.0% YoY), and the FY2025 full-year result was $5.8 million, up 31.08% from the prior year.
• Non-Current Assets for Q1 2026 stood at $5.9 million, up from $5.8 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $7.2 million in Q1 2022 and bottomed at $2.5 million in Q2 2024.
• The 5-year median for Non-Current Assets is $5.2 million (2023), against an average of $5.1 million.
• The widest annual swing landed in 2022, when Non-Current Assets surged 2367.92%; it then sank 44.26% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $5.7 million in 2022, then slumped by 38.59% to $3.5 million in 2023, then increased by 26.68% to $4.5 million in 2024, then soared by 31.08% to $5.8 million in 2025, then climbed by 1.49% to $5.9 million in 2026.
• The last three Non-Current Assets figures came in at $5.9 million (Q1 2026), $5.8 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.

Peer Comparison